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Insights into Hunter syndrome from the structure
of iduronate-2-sulfatase
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Hunter syndrome is a rare but devastating childhood disease caused by mutations in the IDS
gene encoding iduronate-2-sulfatase, a crucial enzyme in the lysosomal degradation pathway
of dermatan sulfate and heparan sulfate. These complex glycosaminoglycans have important
roles in cell adhesion, growth, proliferation and repair, and their degradation and recycling in
the lysosome is essential for cellular maintenance. A variety of disease-causing mutations
have been identiﬁed throughout the IDS gene. However, understanding the molecular basis of
the disease has been impaired by the lack of structural data. Here, we present the crystal
structure of human IDS with a covalently bound sulfate ion in the active site. This structure
provides essential insight into multiple mechanisms by which pathogenic mutations interfere
with enzyme function, and a compelling explanation for severe Hunter syndrome phenotypes.
Understanding the structural consequences of disease-associated mutations will facilitate the
identiﬁcation of patients that may beneﬁt from speciﬁc tailored therapies.
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H
unter syndrome, also known as Mucopolysaccharidosis
type II (MPS II, OMIM 309900)1, is an X-linked
lysosomal storage disease caused by genetic deﬁciency of
the enzyme iduronate-2-sulfatase (IDS, EC 3.1.6.13), required for
the step-wise degradation and recycling of complex
glycosaminoglycans (GAGs). IDS belongs to the sulfatase family
of enzymes and catalyses hydrolysis of the C2-sulfate ester bond
at the non-reducing end of 2-O-sulfo-a-L-iduronic acid residues
in dermatan sulfate and heparan sulfate. Loss of IDS activity leads
to abnormal accumulation of GAGs in multiple tissues and
organs, resulting in progressive cellular and multi-organ
dysfunction.
Signs and symptoms of Hunter syndrome include coarse facial
features, stiff joints, skeletal abnormalities, hepatosplenomegaly,
cardiovascular and respiratory disorders, developmental delay
and deteriorating intellectual function. In general, the disease
progression follows one of two forms. ‘Severe’ early-onset disease
becomes apparent within 2–4 years of age, patients exhibit
behavioural disturbances and progressive intellectual disability
concomitant with neurodegeneration; death occurs before
adulthood. In contrast, patients with the ‘mild’ late-onset form
preserve normal or slightly impaired intelligence and survive into
late adulthood2. The incidence of Hunter syndrome is B1 in
100,000 male live births, but varies considerably between different
populations3,4. Sporadic cases have been reported in females.
Over 500 mutations at the IDS locus (Xq28) have been identiﬁed,
including complex rearrangements, insertions/deletions, splicing
defects and missense/nonsense point mutations. This molecular
heterogeneity results in a broad spectrum of disease phenotypes,
and combined with the rarity of individual mutations, the fact that
most mutations are private/familial, and the lack of standardized
severity reporting, genotype/phenotype correlations have been
difﬁcult to establish5,6. A notable exception to this is that patients
harbouring gross structural changes in the IDS gene, caused by
deletions or gene–pseudogene recombination events, usually
develop severe forms of Hunter syndrome7. Prediction of the
clinical phenotype can also be hindered by effects of other
mutations in multiple genes that may contribute to the spectrum
of disease8. However, differences in measured level of GAG
synthesis (presumably also affected by genotype) can be harnessed
to improve the prediction of disease phenotype9.
There is no curative treatment for Hunter syndrome that is
currently approved, and management is usually symptomatic
and supportive. Enzyme replacement therapy (ERT)10 with
recombinant human IDS (Elaprase, Shire Pharmaceuticals)11 is
effective in ameliorating peripheral symptoms associated with
the ‘mild’ disease form, with recipients showing improved excretion
of GAGs in urine, reduced liver and spleen size and some bone
remodelling. However, ERT cannot prevent or reverse the
characteristic cardiac and neurological deterioration of the ‘severe’
form, and for many patients treatment remains palliative12,13.
Pharmacological chaperone therapy may be a useful alternative
strategy for folding mutants with residual catalytic activity, as has
been demonstrated for other lysosomal storage disorders14.
Here we report the X-ray crystal structure of human IDS with a
sulfate ion bound covalently in the active site. Despite low
sequence identity, the overall fold and domain organization bears
a striking core resemblance to other human sulfatases. This
structure generates insight into the catalytic mechanism and
provides a framework for better understanding the consequences
of disease-associated missense mutations.
Results
Protein characterization. Clinical-grade IDS was provided by
Shire Pharmaceuticals in the form of a B76 kDa glycoprotein,
recombinantly expressed in HT-1080 human ﬁbroblasts,
and puriﬁed following secretion into growth medium. Upon
denaturation and treatment with PNGase F, IDS can be
deglycosylated to a single B58 kDa species (Supplementary
Fig. 1a). To verify that glycosylated samples for crystallization
were catalytically active, assays were performed with
the ﬂuorogenic substrate 4-methylumbelliferyl-a-L-iduronide-2-
sulfate (MU-aIdoA-2S, Supplementary Fig. 1b). Using this sys-
tem, we report a speciﬁc activity of 36 mmol h 1mg 1 at room
temperature (293K). This is comparable to the commercially
reported activity of Elaprase (46–74 mmol h 1mg 1), as
determined with heparin disaccharide substrate at 310K.
Overall structure and post-translational modiﬁcations.
The crystal structure of IDS was reﬁned at 2.3 Å resolution.
Extensive crystal optimization was required to obtain the best
possible diffraction data, because loose crystal packing in the ab
plane of the crystal (Supplementary Fig. 2) led to varying levels
of anisotropy (Table 1). The enzyme is monomeric with a
single-polypeptide chain in the asymmetric unit. IDS adopts a
compact, globular a/b sandwich fold, comprising residues 34–550
(Fig. 1). The ﬁrst 33 residues, encoding the N-terminal signal
peptide and propeptide, are cleaved during enzyme secretion and
therefore are not present in the structure15. Lack of interpretable
electron density prevented the modelling of one loop region
(residues 444–453). A second shorter loop (residues 386–392) is
very poorly ordered, but modelled with high local B-factors into
weak electron density.
Traditionally, the IDS main chain has been described as two
subdomains, SD1 and SD2, corresponding to fragments resulting
from lysosomal proteolytic processing events16. The N-terminal
SD1 (residues 34–443) comprises the ‘heavy’ 42 kDa chain, and
the C-terminal SD2 (residues 455–550) corresponds to the ‘light’
14 kDa chain (Fig. 1a). The lack of visible electron density in
the unmodelled loop between the two subdomains (residues
444–453) is consistent with a disordered region that is susceptible
to proteolytic cleavage. In our structure this loop, although
disordered, is likely to remain intact as the protein is puriﬁed
from conditioned medium and has not trafﬁcked to lysosomes.
This is consistent with the presence of a single-band visible by
SDS–PAGE following denaturation and deglycosylation
(Supplementary Fig. 1a).
SD1, which contains the catalytic core, is characterized by a
central 7-stranded b-sheet (one antiparallel and six parallel
strands) surrounded by ten a-helices/helical turns and ﬁve short
b-strands. The C-terminal SD2 consists of a twisted, 4-stranded
antiparallel b-sheet capped by a short C-terminal a-helix and
ﬂanked by ﬁve helical turns. Together, SD1 and SD2 form a
large hydrophobic packing interface with a buried area of
B1,850Å2. Hence, they remain stably associated and together
form the major 58 kDa ‘intermediate’ form seen here which is
enzymatically active (Supplementary Fig. 1b). At the C-terminus,
an 18-residue loop terminates in a short a-helix, which packs
against the hydrophobic region of the SD2 b-sheet.
Out of the six cysteines in the mature IDS polypeptide, four are
observed to form disulﬁde bonds. The C171–C184 bridge links
short b-strands near the putative substrate recognition site, while
the C422–C432 linkage participates in stabilization of an
extended (4 30 residue) solvent-exposed loop region. Both
disulﬁde bonds are functionally important, as mutation of any of
these cysteines causes Hunter syndrome (Supplementary
Table 1). One free cysteine is found at the tip of an 18-residue
loop connecting strand b1 of the major b-sheet and N-terminal
a-helix 1. The other, C84, is post-translationally modiﬁed as a key
catalytic residue in the active site.
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The IDS sequence contains eight putative N-linked
glycosylation sites (Fig. 1a). Continuous electron densities were
observed adjacent to all asparagine residues involved in N-linked
glycosylation, and at least one N-acetylglucosamine moiety linked
to the nitrogen of the asparagine side chain was built at each
predicted site.
Comparison to other sulfatase enzymes. To date, 17 genes
encoding human sulfatases have been identiﬁed. Amino acid
sequences vary signiﬁcantly amongst members of the sulfatase
family, and pairwise alignment of IDS with other human
sulfatases reveals only B20% sequence identity, with greater
conservation in N-terminal regions (Supplementary Fig. 3). X-ray
crystal structures have been determined of human sulfatases
arylsulfatase A (ARSA)17, arylsulfatase B (ARSB)18 the
membrane-associated estrone or steroid sulfatase (STS, also
known as arylsulfatase C)19, galactosamine-6 sulfatase
(GALNS)20 and N-sulfoglucosamine sulfohydrolase (SGSH)21.
Deﬁciencies of these enzymes also lead to rare inherited disorders:
metachromatic leukodystrophy, Maroteaux–Lamy syndrome
(MPS VI), X-linked ichthyosis, Morquio A syndrome (MPS IV
A) and Sanﬁlippo A syndrome (MPS III A), respectively.
Structural alignments reveal signiﬁcant topological similarity
between N-terminal regions of IDS and other sulfatases,
concentrated around the central b-sheet in SD1 (Fig. 2a, 174
residues with backbone Ca RMSDo2.0). Beyond this, poor
conservation of surface loops and divergent C-terminal sequences
prevent main-chain superposition, but the 4-stranded b-sheet in
SD2 is a feature shared by all human sulfatases. Nevertheless,
several large differences are observed. The central b-sheet at the
core of IDS is formed by seven strands in contrast to ten for
O-sulfatases ARSA, ARSB, STS and GALNS, more closely
resembling the 8-stranded core of SGSH, an N-sulfatase. This
has consequences for the shape of the putative substrate-binding
region. In IDS, the cleft is relatively wide and shallow, while in
other sulfatases it forms a narrower cavity, deepening towards the
catalytic site (Fig. 2b–e). In arylsulfatases A and B this cavity is
extended by three additional strands of the central b-sheet; in
STS, the two transmembrane helices emerge from the globular
domain directly adjacent to the substrate-binding cleft, forming a
deep-binding pocket (Fig. 2e). Differences are also observed in the
C-terminal regions; most notably the very extensive C-terminal
loops or b-meander motifs present in other sulfatases are absent
from IDS. In ARSA, ARSB and GALNS these C-terminal
extensions help to deﬁne the substrate-binding pockets. In IDS,
the four antiparallel strands comprising the SD2 b-sheet are
considerably longer than those of other sulfatases, and hence a
greater contribution to the shape of the substrate-binding cleft
comes directly from SD2.
Substrate-binding cleft and active site. Despite highly divergent
sequences and the diversity of substrates processed by these
enzymes, the active-site residues (red stars in Supplementary
Fig. 3) are highly conserved and are almost completely
superimposable in all six sulfatase structures (Fig. 2f), providing
strong support for a common catalytic mechanism. The active site
of IDS is located in a cleft comprising many basic residues,
conferring a positive electrostatic surface potential consistent with
binding negatively charged polymeric substrates (Figs 3a and 1b).
The catalytic residue C84 is situated at the N-terminus of helix 2,
opposite the central b-sheet. In all eukaryotic sulfatases, the thiol
group of this residue is oxidized to Ca-formylglycine (FGly,
2-amino-3-oxopropionic acid), an essential modiﬁcation required
for catalytic activity22. This modiﬁcation is performed by
FGly-generating enzyme (FGE), which recognizes the highly
conserved sequence motif CxPSR during translocation of the
Table 1 | Data collection and reﬁnement statistics.
IDS-native (5FQL) IDS-GdCl3 IDS-NaI
Data collection
Wavelength (Å) 0.9763 1.475 0.9763
Space group P 31 1 2 P 31 1 2 P 31 1 2
Cell dimensions
a, b, c (Å) 71.1, 71.1, 285.9 68.8, 68.8, 289.0 72.6, 72.6, 286.4
a, b, g () 90, 90, 120 90, 90, 120 90, 90, 120
Resolution (Å) 35.52–2.30 (2.39–2.30)* 80.0–3.28 (3.36–3.28) 62.90–3.50 (3.70–3.50)
Rmerge 0.080 (0.944) 0.166 (2.67) 0.075 (1.17)
oI/sI4 12.4 (1.9) 17.4 (1.3) 18.2 (2.6)
CC(1/2) 0.997 (0.781)  
Completeness (%) 96.2 (97.7) 99.0 (92.1) 99.2 (99.8)
Redundancy 5.3 (5.2) 15.8 (10.0) 11.5 (11.7)
Anisotropic DB (Å2) 38 117 134
Reﬁnement
Resolution (Å) 35.53–2.30 (2.38–2.30)  
No. reﬂections 35,738 (3,605)  
Rwork/Rfree 0.181/0.210  
No. atoms (excl. H)
Protein 4,269  
Water 213  
B-factors
Protein 67.7  
Water 57.3  
R.m.s.d.
Bond lengths (Å) 0.004  
Bond angles () 0.655  
r.m.s.d., root mean squared deviation.
*Values in parentheses are for highest-resolution shell. One crystal was used per structure.
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nascent (and unfolded) polypeptide chain into the endoplasmic
reticulum (ER) lumen23,24. FGly functions catalytically as an
aldehyde hydrate (FGly aldehyde-hydrate, FGH) with two
geminal hydroxyl groups; here we observe what we have
interpreted as a covalent sulfate-ester intermediate (FGly
sulfate, FGS) in the IDS active site (Fig. 3b), which could
originate from natural substrate encountered in cells during
expression. An alternative interpretation that this is a phosphate
picked up from the storage buffer, as proposed for SGSH21,
cannot be excluded on the crystallographic evidence. However,
the higher stability of sulfate esters makes this the more likely
interpretation.
Extra electron density for a metal ion was observed next to the
modiﬁed FGS residue. This was modelled as Ca2þ , coordinated
by one nitrogen and ﬁve oxygen atoms with approximate
octahedral geometry: one oxygen each from the side chains of
D45, D46 and D334; two sulfate oxygens from FGS84 and
one nitrogen from the side chain of H335. (Fig. 3c). The
metal–oxygen bond distances range from 2.3Å to 2.5 Å,
corresponding to the expected values for calcium25. The second
carboxylate oxygen of D334 forms an additional longer
interaction of 3.3 Å. Successive temperature factor reﬁnements
for bivalent cations Ca2þ , Mn2þ and Mg2þ resulted in values of
55.2 Å2, 65.4 Å2 and 39.7 Å2, respectively; the B-factor for a Ca2þ
ion correlates best with the average B-factor (52Å2) of the
coordinating side chain atoms25. Calcium was also identiﬁed in
the metal-binding pocket of human ARSB18, STS19, GALNS20,
SGSH21 and Pseudomonas aeruginosa arylsulfatase (PAS)26 whilst
in human ARSA, both magnesium and calcium have been
described17,27. With its lower Lewis acidity, Ca2þ is more
consistent than Mg2þ with the stability of the observed
sulfate-ester modiﬁcation of formylglycine: in related structures,
the identiﬁcation of either a sulfate ester (ARSB18, STS19) or
phosphate ester (ARSA17,27, SGSH21) modiﬁcation correlates
with the identiﬁcation of the metal ion as Ca2þ . The presence of
divalent metal ions in sulfatases is thought to be essential for
active-site stabilization and sulfate-ester formation28.
Nine out of ten IDS active-site residues are highly conserved
among sulfatases: D45, D46, C84, R88, K135, H138, H229, D334
and K347. The histidine residue at position 335 is replaced in
most sulfatases by asparagine, and by glutamine in STS
(Supplementary Fig. 3). Side chains of conserved H138 and
H229 likely play important roles in catalysis, making direct
contacts with the free geminal hydroxyl of FGS and a sulfate
oxygen (OS3) of FGS, respectively. The positively charged groups
of R88, K135 and K347 make several structural interactions
within the catalytic core. R88 stabilizes the orientation of
metal-binding residues D45 and D334 and interacts with the
free geminal hydroxyl of FGS; K135 also interacts with D45 to
correctly orient the side chain for metal-binding. D46 is
positioned for metal-binding via interactions with K347 and
W337. The sulfate moiety of FGS is stabilized by hydrogen bonds
with the side chains of D46, K135, D334 and K347 and, via a
water molecule, to the side chains of Y348 and K479 (Fig. 3d).
Attempts to obtain an enzyme–substrate complex structure by
co-crystallization or soaking with a variety of ligands were not
successful. Nevertheless, to gain insight into possible modes of
substrate binding, we performed docking experiments with
2-sulfo-iduronic acid, heparan sulfate disaccharides and a
dermatan sulfate disaccharide, restraining the position of the
scissile sulfate group adjacent to the catalytic FGH residue
with appropriate geometry for attack (Fig. 3e). This demonstrates
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Figure 1 | X-ray crystal structure of IDS. (a) Annotated diagram of the IDS sequence, showing the ER signal peptide and propeptide (grey), subdomains
(SD) 1 and 2 (light blue and purple, respectively), active-site residues (black), disulﬁde bridges (yellow) and N-linked glycosylation sites (pink). (b) Natural
IDS substrates heparan sulfate (with a1-4 linkage) and dermatan sulfate (a1-3 linkage). The sulfate group removed by IDS is indicated (red). The residue at
the þ 1 position can be either D-glucosamine or D-galactosamine, with variable substituents at C2N, C3, C4 and C6 positions (X¼H/SO3 ; Y¼H/SO3/
COCH3) (c) Ribbon diagram of IDS coloured by subdomain, shown in three orthogonal views. Disulﬁde bonds (yellow spheres), calcium ion (grey sphere)
and glycans (pink sticks) are shown. The active site is indicated by grey sticks.
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that it is possible to place the substrate in a favourable orientation
consistent with our mechanistic understanding. The 2S-IdoA
monosaccharide binds in a low energy 4C1 conformation, making
additional hydrogen bonds to R273, N167 and Y348 from SD1,
and K479 from SD2. The substrate-binding cleft is large enough
to accommodate both the heparan sulfate (a1–4 linkage) and
dermatan sulfate (a1–3 linkage) disaccharides with different
substituents at the þ 1 position: H226, K479 and K135 can make
polar contacts with additional OH, SO3 or COCH3 groups.
Different ring puckers of 2S-IdoA (ref. 29) may also be tolerated
by the binding site. An analysis of mean B-factors per residue
reveals that the residues proximal to the scissile sulfate are well
ordered, indicating that the active site is likely preorganised.
However, K479 and D269 are likely ﬂexible and may change
conformation to accommodate the diverse and heterogeneous
substrates processed by this enzyme.
Discussion
Two mechanisms for sulfate-ester hydrolysis have been proposed
based on crystal structures of human ARSA, human ARSB and
Pseudomonas arylsulfatase (PAS), and studies on the enzyme
kinetics of active-site mutants30. Most recent experimental
evidence supports the transesteriﬁcation-elimination (TE)
mechanism, in which the catalytically relevant species is an
FGly aldehyde-hydrate (FGH) with a second geminal hydroxyl.
The arrangement of the IDS active site is compatible with the
consensus TE mechanism, hence we propose a similar
mechanism for IDS in which FGH84 performs an SN2
nucleophilic attack on the sulfur atom to generate the covalent
FGS adduct, followed by elimination of bound sulfate and
rehydration of the resultant FGly aldehyde. In particular, H229,
H138, D334 and K347 are likely to play active roles in proton
transfer or activation of water during the reaction cycle, as
proposed for other sulfatases.
Interestingly, we observe a sulfate ion bound in the active site,
similar to the observed ‘resting state’ of ARSB and STS. The
covalent linkage is unambiguous, with a distance of 1.5 Å between
the sulfur atom and the FGS ester oxygen. Attempts to reﬁne a
non-covalently bound sulfate ion adjacent to an FGH residue, as
seen in the high-resolution PAS structure, did not agree with the
electron density present in the IDS structure (Supplementary
Fig. 4). Due to the dependency on general acid/base catalysis, it is
likely that sulfate elimination will only occur efﬁciently at the
optimum lysosomal pH of B 4.8, and not in the storage buffer
(pH 7.5) or crystallization buffer (pH 6.1). Indeed, despite this
observed sulfate ion, IDS samples were enzymatically active at pH
5.0 (Supplementary Fig. 1b).
To date, 542 pathogenic mutations in the IDS gene have
been identiﬁed in patients with Hunter syndrome (Supplemen-
tary Table 1). The mutation spectrum is diverse and ranges from
small point mutations, deletions and insertions to truncations,
large IDS gene deletions and complex rearrangements. A large
proportion of mutations associated with Hunter syndrome are
missense mutations randomly distributed throughout the protein
sequence, with 217 amino acid substitutions described at 128
positions (Fig. 4). These are likely to result in protein misfolding,
catalytic inactivation, premature degradation or failure of
lysosomal targeting. However, at least ﬁve of these are likely to
be false positives, as they are found in the Exome Aggregation
Consortium database31 at a frequency too high to be consistent
with a role in this rare disease (Supplementary Table 1).
The structure of IDS provides detailed insight into the
consequences of many disease-associated mutations. Several
mutations directly affect the catalytic core of the enzyme, either
by direct substitution of key active-site residues, interference
with metal ion coordination, indirect active-site destabili-
zation/distortion or corruption of the CxPSR motif necessary
for the essential FGly modiﬁcation (Fig. 4). Such changes are
likely to eliminate or severely reduce catalytic activity with grave
phenotypic consequences; for example R88H/C/P/L/G/S muta-
tions and K347I/Q/T/E mutations often lead to severe, early-
onset disease.
Outside the active site, a small number of mutations are located
on the solvent-accessible surface of the enzyme. These include
substitutions that alter local surface charge (E125V) and others
that interfere with N-linked glycosylation by either removal of
existing sites (N115I/Y, S117Y), or aberrant introduction of new
glycans (T130N) (Fig. 4). As well as causing misfolding, incorrect
glycosylation may interfere with lysosomal targeting by impaired
binding to the mannose-6-phosphate receptor.
In contrast to those affecting the enzyme surface, nearly 90%
of pathogenic missense mutations involve amino acids that
are buried within the fold of IDS (Supplementary Table 1).
The expected severity of these mutations is variable and
consequences range from local destabilization and misfolding to
global unfolding, leading to premature degradation. In the tightly
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Figure 2 | Structural alignment of IDS with other human sulfatase
enzymes. (a) Secondary structure-based superposition of IDS (blue),
ARSA (pink), ARSB (green), STS (yellow), GALNS (slate) and SGSH
(dark red) in two orthogonal views. Active-site residues are shown as
grey sticks. Inset: core structural elements shared by all human sulfatases,
showing only conserved regions with backbone Ca RMSDo2.0Å.
(b–e) Cutaway diagrams of the substrate-binding cleft of IDS, ARSA,
ARSB and STS, coloured as above. Active-site residues are shown as grey
sticks. (f) Least squares superposition of conserved active-site residues,
coloured as above. The metal ions are shown as grey spheres.
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packed hydrophobic core surrounding the central b-sheet,
several such mutations (L41P, L67P, L72P, L73F, L221P,
L314P/H, L403R and L410P) would introduce main-chain
geometry distortion or buried steric clashes, disrupting the local
secondary structure in the core of SD1 (Fig. 4). In SD2,
the guanidinium group of R468 participates in a buried
hydrogen bonding network and hydrophobic stacking
interactions stabilizing several nearby loops, helical turns and
b-strands (Fig. 4, Supplementary Fig. 5). Mutation of this residue
(R468Q/L/W/G/P) is associated with a range of Hunter disease
phenotypes from mild to severe.
In general, proteins with folding defects will be retained by the
ER quality control machinery, preventing trafﬁcking through the
Golgi apparatus and ﬁnal delivery to lysosomes32. In experiments
with COS cells, transiently expressed P86L/R and P480L/Q
mutants did not efﬁciently trafﬁc to lysosomes33. However,
misfolding does not always lead to catalytic inactivation, and
several IDS missense mutants with residual enzyme activity have
been identiﬁed33–37. Such mutants could be promising candidates
for treatment by pharmacological chaperone therapy (PCT). PCT
relies on use of small molecules which selectively bind and
stabilize target proteins, shifting the folding equilibrium towards
functional material, thus alleviating ER retention and increasing
lysosomal delivery. This therapeutic approach is under active
development for several other lysosomal storage disorders
including Pompe38, Fabry39, Gaucher40,41 and Krabbe
disease42,43. As well as the IDS active site, several other surface
pockets with different electrostatic potentials are present which
may be exploited for future chaperone development
(Supplementary Fig. 6).
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2mFODFC, contoured at 0.35 e Å 3) for IDS active-site residues (grey sticks) and the Ca2þ ion (grey sphere). (c) Details of the Ca2þ ion coordination
(yellow dashed lines) in the IDS active site. (d) Schematic representation of amino acid side chain interactions with the covalently-modiﬁed FGS84 residue.
Hydrogen bonds (yellow dashed lines) are shown. (e) Docked structures of 2-sulfo-iduronic acid, two variably sulfated heparan sulfate disaccharides and a
dermatan sulfate disaccharide, showing details of the putative substrate-binding region. Hydrogen bonds (dashed yellow lines) are indicated. For
solvent-accessible residues situated in the substrate-binding cleft, a graph of average B-factor per residue is shown. The mean B-factor for all IDS
non-hydrogen atoms is indicated with a dotted line.
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IDS variants with disruptive mutations such as complete
deletions or large rearrangements will not be amenable to PCT,
and patients carrying such mutations are also more susceptible to
the development of neutralizing antibodies that reduce the
efﬁcacy of ERT44. Knowledge of the structure of IDS could also
facilitate structure-based de-immunization45,46 of the protein
used in ERT, to remove T-cell epitopes while preserving a stable
structure.
The structure of IDS described here provides a much-needed
snapshot of the enzyme defective in Hunter syndrome, delivering
a detailed atomic framework for the rationalization and further
understanding of disease-causing mutations, and supplying
‘blueprints’ for the future development of new PCT agents or
less immunogenic protein for ERT. In addition, details of the
active site support a likely catalytic mechanism shared by other
sulfatases, adding to our understanding of this family of enzymes.
Methods
Deglycosylation experiments. IDS protein in 100mM NaCl, 10mM Tris HCl
pH 7.5 was denatured by the addition of urea up to 2.5M ﬁnal concentration.
Samples were treated with PNGase F (Sigma) as directed by the manufacturer (5 h,
310K) before analysis by reducing SDS–PAGE.
Enzyme activity assay. Fluorogenic assays were performed based on the methods
of Voznyi et al.47 and Tolun et al.48. In brief, the sulfate group on substrate
4-methylumbelliferyl-a-L-iduronide-2-sulfate (MU-aIdoA-2S) is hydrolysed by
IDS, upon which the desulfated product 4-methylumbelliferyl-a-L-iduronide
(MU-aIdoA) becomes a substrate for reporter enzyme a-iduronidase, which
cleaves MU-aIdoA to generate ﬂuorescent product 4-methylumbelliferone.
Substrates and reporter enzymes were obtained from Moscerdam Substrates.
Reactions of 50 ml comprised 0.3mM MU-aIdoA-2S, 1.3 nM IDS (100 ngml 1)
and excess a-iduronidase reporter enzyme in 0.1 M sodium acetate pH 5.0, 10mM
lead acetate, 0.01% Tween-20. Reactions were incubated at room temperature
(293 K) for 60min before termination with 200ml stopping buffer (0.5M Na2CO3
pH 10.7, 0.025% Triton X-100). Liberated 4-methylumbelliferone was quantiﬁed by
measuring ﬂuorescence (lex¼ 365 nm; lem¼ 445 nm) with a SpectraMax M2 plate
reader (Molecular Devices).
Protein preparation and crystallization. Puriﬁed recombinant human IDS
(Elaprase) was kindly provided by Shire Pharmaceuticals. Crystallization trials were
carried out with both glycosylated and deglycosylated protein, but considering that
no improvement in diffraction quality was observed after deglycosylation and that
the two crystal forms were isomorphous, the glycosylated material was used for
structure determination. IDS was buffer-exchanged by dialysis (10-kDa molecular
mass cut-off; Thermo Scientiﬁc) into 100mM NaCl, 10mM Tris HCl pH 7.5 and
concentrated to 10.0mgml 1 using Amicon Ultra 10-kDa molecular mass cut-off
centrifugal concentrators (Millipore). Crystals were grown at 20 C by hanging
drop vapour diffusion. In total, 1.0 ml of protein was mixed with 1.0 ml reservoir
solution (0.1M MES-NaOH pH 6.1, 1.0M LiCl and 20% wt/vol PEG 6K) and
equilibrated against 1.0ml reservoir solution. Crystals were cryoprotected by
transferring to a drop of cryo solution (equilibrated reservoir solution increased to
30% wt/vol PEG 6K and supplemented with 20% wt/vol ethylene glycol) for 30 s
before ﬂash-cooling in liquid nitrogen.
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Figure 4 | Disease-associated mutations of IDS. (Top) Annotated diagram of the IDS protein, indicating positions of all known Hunter syndrome missense
mutations. All residues that are mutated are shown as sticks (purple) on the structure of IDS, coloured as above. Different mutations have different
consequences; for a selection of these a more detailed view is provided (Insets) showing the surrounding region of the structure that is perturbed.
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Crystal soaks for experimental phasing. For the NaI-derivative data set, crystals
were soaked sequentially in cryo solution (above) supplemented with 0.4 M NaI
(1min) and 1.0M NaI (5min). For the GdCl3-derivative data set, crystals were
prepared by soaking in cryo solution supplemented with 50mM GdCl3 (30min).
Crystals were then ﬂash-cooled as above.
Crystallographic structure determination and analysis. Data collection and
processing statistics are detailed in Table 1. All data sets were collected at a tem-
perature of 100 K. Diffraction data were recorded at Diamond Light Source
beamline I03 on a Pilatus 6M detector (Dectris). The native data set was collected
at l¼ 0.9763Å over a 360 oscillation range with t¼ 0.15 s and DF¼ 0.2  per
image. Diffraction data were processed using the XIA2 pipeline49 implementing
MOSFLM50 for indexing and integration, POINTLESS51 for point group
determination and AIMLESS52 for scaling and merging. iMOSFLM50 was also used
for manual indexing and integration. Resolution cut-off was decided by CC1/240.5
and hI/sIiZ1.8 in the outer resolution shell53. The NaI-derivative data set was
collected as above; an initial attempt to collect data at the iodide peak wavelength
suffered from excessive radiation damage. The GdCl3-derivative data set was
collected at l¼ 1.475 Å.
SAD phases useful to about 3.8 Å resolution were determined for the GdCl3-
derivative crystal with phenix.autosol54, which found 4 Gd sites. The resulting
electron density was not interpretable but allowed docking of known sulfatase
structures to aid further interpretation; the best agreement was obtained with PDB
entry 3B5Q, a putative sulfatase from Bacterioides thetaiotaomicron VPI-5482.
Electron density cut out from the SAD map, using the docked sulfatase structure as
a mask, was used to solve the native and iodide-soak data by molecular
replacement in Phaser55. A substructure of 11 iodide sites was then determined
using SAD log-likelihood-gradient maps56, starting from the electron density
model. At this point, initial phase information, a molecular mask, and operators
relating the positions of IDS in the three crystals were available, allowing averaging
to be carried out with phenix.multi_crystal_average57. An iterative process of cycles
of automated model-building with phenix.autobuild58, followed by determination
of updated substructures (ultimately 8 sites for the GdCl3 derivative and 13 sites for
the iodide soak) and multi-crystal averaging, eventually led to a model comprising
405 of 517 residues, with Rfree¼ 0.42.
All further model building and reﬁnement was performed iteratively using
COOT59 and phenix.reﬁne60 (Table 1). The Protein Data Bank ﬁle and CIF
restraints for the non-standard FGS84 residue were generated using eLBOW61.
Hydrogens were reﬁned in the riding position. MolProbity62 was consulted
throughout the reﬁnement process, at the end of which 95.4% of residues were in
the favoured Ramachandran region and none were outliers. Estimation of buried
surface area in the IDS structure was carried out using PISA63. For the electrostatic
potential calculations, partial charges were assigned using the PDB2PQR server64,
implementing PROPKA65 to estimate side chain pKa values. Electrostatic surfaces
were calculated using APBS66 and structural ﬁgures were rendered using PyMOL
(Schro¨dinger LLC). Two-dimensional hydrogen bonding diagrams were created
using LigPlotþ (ref. 67).
Docking. To prepare the protein model for docking, the sulfated FGS84 residue
was replaced with FGH (Protein Data Bank code DDZ: 3,3-dihydroxy L-alanine)
and waters and glycans were removed. Ligand PDB ﬁles for 2-sulfo-iduronic acid
and various heparan sulfate and dermatan sulfate disaccharides were generated
with the GLYCAM-Web GAG builder (http://glycam.org) and minimized with
PRODRG68. All docking was performed with HADDOCK 2.2 (ref. 69) using the
WeNMR grid service70. Residues FGH84, Ca2þ , K135, K347 and H229 were
speciﬁed as active, with passive residues deﬁned automatically within a 6.5 Å radius
of active residues. Unambiguous distance restraints were enforced to maintain the
correct orientation of the nucleophile (via interaction with H138) and preserve
Ca2þ coordination geometry during docking. For ligands with multiple sulfate
groups, an additional restraint was provided to juxtapose the relevant iduronate-2-
sulfate group close to the active site.
Amino acid sequence alignment. Primary sequences for known human sulfatases
were retrieved from the UniProt database71 and annotated ER signal peptides
were removed. Sequences were aligned by using ClustalW72, and graphical
representations of the alignment were prepared using ALINE73.
Data availability. The atomic coordinates and structure factors for IDS have been
deposited in the wwPDB under accession code 5FQL. All other data are available
from the corresponding author upon reasonable request.
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